Citations: Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C

Views

CrossRef citations to date

Altmetric

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Douglas D DeCarolis, Yi-Chieh Chen, Anders D Westanmo, Christopher Conley, Amy A Gravely & Fatima B Khan. (2019) Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. American Journal of Health-System Pharmacy 76:17, pages 1273-1280.
Crossref

Marc Puigvehí, Beatriz De Cuenca, Ana Viu, Moisés Diago, Juan Turnes, Francisco Gea, Juan M. Pascasio, Sabela Lens, Joaquín Cabezas, Ester Badia, Antonio Olveira, Rosa M. Morillas, Xavier Torras, Silvia Montoliu, Patricia Cordero, José L. Castro, Javier Salmerón, Esther Molina, Juan J. Sánchez‐Ruano, Javier Moreno, María D. Antón, José M. Moreno, Juan De la Vega, José L. Calleja & José A. Carrión. (2018) Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort. Liver International 39:1, pages 90-97.
Crossref

Duminda Suraweera, Peter Konyn, Thomas Vu & Sammy Saab. 2019. Clinical Epidemiology of Chronic Liver Diseases. Clinical Epidemiology of Chronic Liver Diseases 229 249 .

Min Gu Kang, Min Jung Kang, Eunhee Ji & Bong Kyu Yoo. (2017) Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. Korean Journal of Clinical Pharmacy 27:3, pages 150-160.
Crossref

Tania M Welzel, Tarik Asselah, Emily O Dumas, Stefan Zeuzem, David Shaw, Rawi Hazzan, Xavier Forns, Tami Pilot-Matias, Wenjing Lu, Daniel E Cohen & Jordan J Feld. (2017) Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2:7, pages 494-500.
Crossref

Uwe Fricke, Lutz Hein & Ulrich Schwabe. 2017. Arzneiverordnungs-Report 2017. Arzneiverordnungs-Report 2017 55 135 .

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date